Allergan announced positive results from a second Phase III trial for the 50 milligram dose of ubrogepant, its drug for acute migraines.
In the trial of more than 1,300 patients, 21.8 percent were pain-free two hours after taking the 50 mg dose versus 14.3 percent on placebo. About 39 percent in the 50 mg group also reported the absence of their most bothersome symptom, such as nausea or sensitivity to light or sound, compared with 27.4 percent for placebo.
A lower dose of ubrogepant failed to meet one of the study’s two main goals, the company said.
Allergan estimates that the highly potent, orally-administered CGRP receptor could bring in $500 million a year.
Read the press release